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Expression of POU1F1 gene, a member of the POU homeodomain family of transcription factors, is necessary for normal differentiation,
development and survival of three anterior pituitary cell types (thyrotrophs, somatotrophs and lactotrophs) and for the proper expression of growth
hormone (GH ), prolactin (PRL), thyroid-stimulating hormone (TSH ) genes and POU1F1 gene itself. Alternative splicing forms of this gene have
been reported in different species, with few functional studies. Apart from the POU1F1-Wild-type with the expected length, in this work we
isolated three additional splicing variants: POU1F1-β, with a 78 bp insert in the trans-activation domain; POU1F1-γ that lacks exon 3 and
POU1F1-δ that lacks exons 3, 4 and 5. Four different protein isoforms were also detected by Western blot in the sheep pituitary tissue. Functional
assays were performed to study the trans-activation of GH and PRL promoters by the splicing variants. Regarding the PRL promoter, the β
variant presented only 12% of the Wild-type trans-activation capacity. Variants γ and δ showed no capacity to trans-activate PRL promoter. Both
γ and δ variants acted as repressors of Wt, reducing significantly the trans-activation made by Wt alone ( p<0.05). Concerning the GH promoter,
the β variant presented a trans-activation capacity 10% higher than Wt. Wt and β variants strongly interact in the activation of GH promoter
doubling the trans-activation potential of Wt. Variants γ and δ showed no capacity to trans-activate the GH promoter and both acted as
repressors, reducing significantly ( p<0.001) the trans-activation performed by Wt. This work presents, for the first time, the characterization of
four splicing forms of Ovis aries POU1F1 gene.
© 2006 Elsevier B.V. All rights reserved.Keywords: Alternative splicing; PIT-1; Sheep; Transcription factor; Gene regulation1. Introduction
POU1F1 (also named PIT-1 or GHF-1) is a member of the
POU homeodomain family of transcription factors (Bodner et al.,Abbreviations: PCR, polymerase chain reaction; RT-PCR, reverse transcrip-
tion-PCR; bp, base pair(s); aa, amino acid; CFS, calf serum; dNTPs,
deoxynucleotide triphosphates; nt, nucleotide(s); cDNA, DNA complementary
to RNA; mRNA, messenger RNA; GH, growth hormone; PRL, prolactin; TSH,
thyroid-stimulating hormone; kDa, kilodalton(s); AMV, avian myeloblastosis
virus; TAD, trans-activation domain; DMEM, Dulbecco's modified Eagle
medium; Wt, Wild-type.
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doi:10.1016/j.gene.2006.05.0281988; Ingraham et al., 1988). It ismainly expressed in the pituitary
and its expression is necessary for the normal differentiation,
development and survival of three adenohypophysis cell types,
thyrotrophs, somatotrophs and lactotrophs (Li et al., 1990;
Simmons et al., 1990). It is also important for the proper expres-
sion of growth hormone (GH ), prolactin (PRL) (Lefevre et al.,
1987; Nelson et al., 1988), thyroid-stimulating hormone (TSH )
(Li et al., 1990) and POU1F1 gene itself (Chen et al., 1990;
McCormick et al., 1990).
The POU1F1 gene, as described by Theill et al. (1989,
1992), contains six exons and five introns and encodes a protein
with 33 kDa. This transcription factor contains two important
regions for the transcriptional regulation of target promoters: a
13E. Bastos et al. / Gene 382 (2006) 12–19N-terminal trans-activation domain (TAD) spanning amino acids
1 to 80 and a C-terminal DNA-binding and dimerization domain
that consists of a POU-specific domain (POUS from aa 128 to 198)
and a POU homeodomain (POUHD from aa 214 to 273). While
POUS and POUHD are essential for high-affinity DNA-binding,
TAD is important for the trans-activation of the target genes.
Until now, POU1F1 encoding cDNAs were cloned in 18
species from three different Classes: Mammalia, Aves and Acti-
nopterygii, as summarized by Bastos et al. (2006).
Alternative splicing is a very common process that allows the
expansion of the proteome. It was mentioned for the first time by
Berget et al. (1977) and it was proposed that 5% of the genes
presented alternative splicing (Sharp, 1994). Later,Modrek andLee
(2002) anticipated that 40 to 60% of the genes undertake alternative
splicing forms and the frequency of this event should be identical
between mammals, flies and worms (Brett et al., 2002). This
number increased to 74% in a study using microarrays (Johnson et
al., 2003) andwas corroborated by the analysis of the transcriptome
of human chromosomes 21 and 22 which showed that alternative
splicing occurs inmore than 80%of the genes (Kampa et al., 2004).
The alternative splicing process was studied in the ratPOU1F1
gene. Theill et al. (1992), Konzak andMoore (1992) andMorris et
al. (1992) published independent results showing an alternative
transcript in this gene, with different nomenclatures: GHF2, Pit-
1β and Pit-1a, respectively. This POU1F1 alternative form arises
from the use of an alternative 3′ splice acceptor at the end of the
first intron and contains an insertion of 78 bp downstream the
nucleotide 142 relatively to the initiation ATG codon, giving rise
to a 26 aa insertion at position 48 of the TAD domain. Functional
analysis of this POU1F1 alternative splicing showed that β
mRNA and protein are 10% less abundant than Wild-type (Wt).
The POU1F1-β and other splicing variants have been described
for other mammalian species, few of them being the object of
functional studies as well. It is the case ofMus musculus (Haugen
et al., 1994), Sus scrofa (Yu et al., 2001),Homo sapiens (Delhase
et al., 1995) and Macaca mulatta (Schanke et al., 1997). The
alternative splicing ofPOU1F1 gene was not detected in nine fish
species analysed. Nevertheless, an insertion of 26 aa (β), similar to
the one detected in birds and mammals, was observed (Chiu et al.,
2002), suggesting a possible important role of this β domain.
In order to study the alternative splicing of POU1F1 gene, we
proposed to analyse the mRNAs expressed in the ovine pituitary.
The bigger size of the sheep hypophysis comparing with rat and
mouse can allow us to achieve a copious amount of mRNAs and
proteins. In this work, we report the identification and character-
ization of four splicing variants of Ovis aries POU1F1 gene: Wt,
β, γ and δ. As far as we know, it is the first time that alternative
transcripts of POU1F1 are identified in sheep. In addition, func-
tional assays were carried out in order to study the ability of all the
variants on the trans-activation of GH and PRL promoters.
2. Material and methods
2.1. RNA extraction
Total pituitary RNAwas isolated from the sheep hypophysis,
using the guanidinium thiocyanate/phenol/chloroform method,described by Chomczynski and Sacchi (1987), and Trizol
reagent (Invitrogen Corporation), according to the supplier's
recommendations.
2.2. RT-PCR of POU1F1
RT-PCRs were optimized in order to identify ovine POU1F1
mRNAs. Primers for RT-PCR reactions were designed based on
the genomic sequences reported by Bastos et al. (2006), with the
GenBank accession nos. AJ549204, AJ549205, AJ549206, and
AJ549207.
Forward primer (P1F), located in exon 1, two bases upstream
of the initiation codon, with the sequence 5′-GAA TGA GTT
GCC AAC CTT TTA CTT CG-3′ was combined with the
reverse primer (P6R), located in exon 6, immediately down-
stream of the stop codon, with the sequence 5′-AAATCT TAT
CTG CAT TCG AGA TGC TCC-3′. To confirm the results, a
second reverse primer was tested (P6aR) with the sequence 5′-
AAA GTA GAA GAG AAA CAC TTC TG-3′, located 130 bp
downstream. The RT-PCRs were performed in two step reac-
tions (Access RT-PCR System, Promega). For the reverse tran-
scriptase reaction, the mix contained 14.4 μl H2O, 1.5 μl MgSO4
25 mM, 5 μl buffer 5×, 0.5 μl dNTPs mix 10 mM, 0.8 μl of
reverse primer 10 μM, 0.5 μl of AMVreverse transcriptase (5 U/
μl) and 1 μl RNA (1 μg/ìl). The reaction was performed at 48 °C
for 45 min and 94 °C for 2 min. At the end of this reaction, 0.5 μl
Tfl DNA polymerase (5 U/μl) and 0.8 μl of reverse primer
(10 μM)were added and PCR amplification was carried out with
the following temperatures: 94 °C for 2 min, and 35 cycles with:
denaturation at 94 °C for 1 min, primer hybridization at 60 °C for
1min; extension at 68 °C for 2min; followed by a final extension
of 7 min at 68 °C.
Another RT-PCR reaction was performed in order to amplify
a cDNA fragment from exon 1 to exon 3. Forward primer (P1aF),
with the sequence 5′-TGT GGG AAT GAG TTG CCA ACC-3′
was combined with reverse primer (P3R), with the sequence 5′-
GGA GAATCC ATG TCTATT GGC T-3′. In this case, RT and
PCR reactions were performed simultaneously, with one-step
mix (OneStep RT-PCR kit, Qiagen), using 5 μl RT-PCR buffer,
1 μl dNTPs 10 mM, 1.5 μl of each primer (10 μM), 1 μl enzyme,
14.5 μl H2O and 0.5 μl RNA (1 μg/μl). The amplification cycle
was as follows: 50 °C for 30 min, 95 °C for 15 min, followed by
30 cycles at 94 °C for 1 min, 60 °C for 1 min and 72 °C for 1 min
and a final extension at 72 °C for 10 min.
The RT-PCR products were separated by electrophoresis on
agarose gels and stained with ethidium bromide. The DNA
fragments obtained were purified and subcloned into pBlue-
script II KS plasmid by T/A cloning. All the constructs were
fully sequenced, in both directions, by the dideoxynucleotide
chain termination method.
2.3. Expression vectors and reporter gene constructs
The four O. aries RSV-POU1F1 plasmids were constructed
by replacing the HindIII–NotI rat GHF-1 coding fragment of
RSVratGHF-1 (Theill et al., 1989) by a similar fragment con-
taining the coding sequence of ovine POU1F1-Wt, -β, -γ and -δ
14 E. Bastos et al. / Gene 382 (2006) 12–19transcripts obtained by HindIII–NotI digestion of previously
sequenced pKS cDNA vectors.
All the constructs were analysed by restriction enzyme
digestion to confirm the direction (EcoRI) and the length (NotI
and HindIII) of the inserts.
2.4. Cell culture and transient transfection assays
HeLa and RAT-6 cells were grown in Dulbecco's modified
Eagle medium (DMEM) (Invitrogen Corporation) supplemented
with 10% calf serum (CFS). In the case of HeLa cells, transient
transfectionswere performed using cationic lipids (Lipofectamine
2000, Invitrogen Corporation) with cells at 90% confluence.
DNAwas mixed with DMEM, while lipofectamine reagent was
mixedwithDMEM, separately. After 5min incubation, theywere
mixed together and incubated at RT for 20 min. During this time,
cells were prepared. The medium was eliminated and a new
medium, with no antibiotics or serum, was added. The complex
lipofectamine–DNA was well mixed within each well and after
5 h of incubation, the medium with serum in double dose was
added to each well. Cells were incubated during 48 h and
subsequently transfected cells were harvested and assayed for
luciferase activity and protein content. In the case of RAT-6 cells,
transient transfections were performed by electroporation. Tripsi-
nized RAT-6 cells were mixed with supercoiled plasmid DNA in
10% CFS DMEM containing Hepes 10 mM and NaCl 30 mM,Fig. 1. Electrophoresis separation of the RT-PCR products of the mRNAs transcribed f
gel C), stained with ethidium bromide. The positions of the splicing variants are sh
obtained in this work were submitted to GenBank under the accession nos. DQ386142
Lane 1: control (without RTenzyme), lane 2: RT-PCR products of sheep RNA, lane 3:
PCR products from sheep RNA, lane 2: control with no RNA, lane 3: 1 kb marker. C: P
and sheep pituitary RNA (lane 2). Lane 3: MassRuler DNA ladder (Fermentas); D: S
and the alternative splicing forms (β: has an extra exon -2A- with 78 bp; γ: lacks ex
presented. Position and direction of the primers are shown with black arrows (P1F andtransferred to an electroporation cuvette, and subjected to an
electrical pulse (220 V, 1050 μF, time constant 35–40 ms), and
then diluted into pre-warmed medium with 10% serum. pRL-
CMV plasmid (Promega) was also used as a transfection-effi-
ciency internal control. Cell survival was typically 30–40% of
that from non-electroporated controls. In both transfection meth-
ods, the plasmids were purified by the QIAGEN plasmid purifi-
cation procedure and an identical level of plasmid DNAwas co-
transfected in each assay, using pKS as carrier DNA. At the
appropriated time, cells were washed twice with phosphate buffer
saline and Firely and Renilla luciferase activities were measured
using the Dual Luciferase Assay (Promega), using a Sirius
Luminometer (Berthold Detection Systems). Results were nor-
malized against Renilla luciferase activity and presented as re-
lative activity with respect to control (considered as 100%) and to
total protein in the extract supernatants. Results were expressed as
the mean fold activation of the promoters±S.E.M. in triplicate.
The significance of the differences between the conditions was
calculated by two-tailed Student's t-tests. Protein assays were
performed according to the Bradford's method, using commer-
cially available reagents (Bio-Rad).
2.5. Protein electrophoresis and Western blot analysis
Proteins were extracted from the same sheep pituitary, using
the protocol described in Trizol reagent (Invitrogen Corporation),romOvis aries POU1F1 gene, in agarose gels (1.5% for gels A and B and 3% for
own in the left side of each picture. The sequences of the alternative splicing
, DQ386143, DQ386144, and DQ386145 X. A: P1F and P6R primers were used.
1 kb molecular marker (Gibco); B: P1F and P6aR primers were used. Lane 1: RT-
1aF and P3R primers were used for the RT-PCR from rat GH3 cells RNA (lane 1)
chematic representation of the sheep POU1F1 gene showing the Wild-type (Wt)
on 3; δ: lacks exons 3, 4 and 5). The theoretical length of the transcripts is also
P1aF located in exon 1; P3R located in exon 3; P6R and P6aR located in exon 6).
Fig. 3. Trans-activation of rat PRL promoter (inserted on luciferase reporter
plasmid) by the Ovis aries expression vector pRSV-POU1F1-Wt and with
increasing amounts of pRSV-POU1F1-γ (A) and pRSV-POU1F1-δ (B), in
HeLa cells. A total DNA amount was maintained using pKS carrier DNA in
each experiment. The cells were analysed for luciferase activity 48 h after
transfection and the results of the average of three repetitions are presented as
fold activation (relatively to the basal expression of each reporter plasmid).
Starred bars are significantly different from Wild-type (⁎p<0.05). A — From
bottom to top: lane 1 — 0.15 μg PRL promoter; lane 2 — 0.15 μg PRL
promoter and 0.3 μg pRSV-POU1F1-Wt; lane 3— similar to lane 2 plus 0.3 μg
pRSV-POU1F1-γ; lane 4 — similar to lane 2 plus 0.6 μg pRSV-POU1F1-γ;
lane 5 — similar to lane 2 plus 1.2 μg pRSV-POU1F1-γ. B — Similar to A,
with increasing the amounts of pRSV-POU1F1-δ.
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protein extract were mixed with 20 μl of 3× sample buffer
(450 mM Tris–HCl pH 6.8; 30% glycerol; 6% SDS; 4.6% DTT
and 0.06% bromophenol blue), sonicated and boiled during
3 min. Proteins were then fractionated by SDS-PAGE at 12%
concentration and electrotransferred to an activated PVDF
membrane (Bio-Rad). Pre-stained SDS-PAGE standard was
used to estimate the MW (kDa) of the detected bands (SeeBlue
Plus2, Invitrogen Corporation). After transfer, the protein
containingmembrane was blocked using ECLAdvance Blocking
Agent (ECL AdvanceWestern Blotting Detection kit, Amersham
Biosciences) and reacted during 1 h with an anti-rat POU1F1
primary antibody diluted 1:500. This antibody was used in the
studies of bovine (Bodner et al., 1988), human (Vila et al., 1993)
and pig (Malagon et al., 1996) POU1F1. This first incubation was
followed by a 1 h incubation with donkey anti-rabbit coupled to
horseradish peroxidase secondary antibody (Amersham Bios-
ciences) diluted 1:50,000. Antibody binding was visualized by
chemiluminescence system (ECL Advance Western Blotting
Detection kit, Amersham Biosciences).
3. Results
3.1. Four different transcripts of POU1F1 gene were detected
in the O. aries pituitary
In order to appraise the existence of new splicing variants of
POU1F1 gene and to understand their function, RT-PCR reac-
tions were performed using RNA purified from ovine pituitary.
Fig. 1-A shows the results of the RT-PCR reaction using primers
P1F, located two bases upstream of the initiation codon, in exon
1, and P6R, located 5 nt downstream of the stop codon, in exon
6. A stronger band, corresponding to approximately 900 bp, was
detected. Additionally, a shorter fragment with approximatelyFig. 2. Trans-activation of rat PRL promoter (inserted on luciferase reporter
plasmid) using different combinations of Ovis aries POU1F1 transcripts
(inserted on expression vectors) in HeLa cells. 0.15 μg of reporter plasmid and
0.45 μg of each expression vector were used in the experiments. A total DNA
amount of 1.5 μg was maintained using pKS carrier DNA. The cells were
analysed for luciferase activity 48 h after transfection and the results of the
average of three repetitions are presented as fold activation (relatively to the
basal expression of each reporter plasmid). Starred bars are significantly
different from Wild-type (⁎⁎p<0.01 and ⁎p<0.05). From bottom to top: lane
1 — promoter alone; lanes 2 to 8: promoter with different combinations of
expression plasmids. Lane 2—Wt; lane 3— β; lane 4— γ; lane 5— δ; lane
6 — (Wt+β); lane 7 — (Wt+γ); lane 8 — (Wt+δ).600 bp was detected and a weaker band with lower molecular
weight was faintly visible. The RT-PCR control on lane 1
(without RT enzyme) confirmed the absence of genomic DNA
contamination.
To corroborate this result, we used a new reverse primer (P6aR)
downstream of P6R to prime the RT-PCR (Fig. 1-B). Three
intense bands were amplified, confirming that they correspond to
the same fragments observed with the previous primers (lane 1).
The control reaction, without RNA (lane 2), confirmed the
absence of contaminations. A third RT-PCR reaction was
performed, using a forward primer (P1aF) located 5 bp upstream
of P1F, in exon 1 and a reverse primer located in exon 3 (P3R). Fig.
1-C shows the result of this RT-PCR using RNA extracted from
ovine pituitary (lane 2) and from rat pituitary GH3 cell line (lane
1). Two fragments of 480 bp and 400 bp were observed, in both
cases, suggesting that the strong upper band in Fig. 1A and Fig.
1B, is the result of two overlapping bands of similar length.
The cloning and sequencing of all the DNA bands detected
in the agarose gels confirmed the existence of four alternative
spliced transcripts of the POU1F1 gene. The sequences were
submitted to GenBank with the accession nos. DQ386142,
DQ386143, DQ386144, and DQ386145. The POU1F1-Wild-
type (Wt) open-reading frame (ORF) showed the expected
length (873 bp) and the same cDNA sequence as compared with
Fig. 4. Trans-activation of rat GH promoter (inserted on luciferase reporter
plasmids) using different combinations ofOvis aries POU1F1 transcripts (inserted
on expression vectors) in RAT-6 cells. The cells were analysed for luciferase
activity 48 h after transfection and the results of the average of three repetitions are
presented as fold activation (relatively to the basal expression of each reporter
plasmid). Starred bars are significantly different from Wild-type (⁎⁎⁎p<0.001).
From bottom to top: lane 1— promoter alone; lanes 2 to 8: promoter with different
combinations of expression plasmids. Lane 2—Wt; lane 3—β; lane 4— γ; lane
5— δ; lane 6— (Wt+β); lane 7— (Wt+γ); lane 8— (Wt+δ).
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leotide differences when compared with another ovine cDNA
sequence (Thomas et al., 2000), suggesting possible poly-
morphisms. An alternative splicing form, named POU1F1-β,
showed a 78 bp insert downstream of the nucleotide 142 relatively
to the ATG initiation codon and a 954 bp ORF. A second
alternative splicing form, we called POU1F1-γ, showed a 651 bp
ORF and it differs fromWt by lacking the entire 225 bp of exon 3.
Finally, a third alternative splicing, with a 426 bp ORF was
showed, lacking the exons 3, 4 and 5, and named POU1F1-δ.Fig. 5. A—Western blot. Total proteins from sheep pituitary were separated on a 12%
were detected with 14; 17; 32 and 36 kDa. B— Schematic illustration of POU1F1 ex
Wt protein (291 aa) are shown. The trans-activation domain (TAD) is divided in TA
(POUS), from aa 128 to 198, includes four α helices. The POU homeodomain (POU
present 317 aa as a consequence of the 26 aa insertion in TAD. Isoforms γ and δ shoul
221), respectively.A schematic representation with all POU1F1 mRNAs
described in the present work is shown in Fig. 1-D: the Wild-
type (Wt) and the three alternative transcripts (β, γ and δ). The
respective length, the particular exon profile and the localization
of the primers used for the RT-PCRs are also shown.
3.2. Trans-activation of the prolactin promoter
The cDNA transcripts with the four POU1F1 ORFs were
subcloned into eukaryotic expression vectors under the control
of RSV promoter (pRSV vectors), in order to perform trans-
activation assays of prolactin (PRL) promoter. Transcription
activation of PRL promoter by the four POU1F1 expression
vectors or by a combination of Wt and all the isoforms were
analysed in non-pituitary HeLa cells (Fig. 2).
The POU1F1-Wt showed a strong trans-activation activity
but POU1F1-β showed only a weak transcriptional activity
(36.4 vs 4.2 fold). POU1F1-γ and POU1F1-δ isoforms did not
trans-activate the PRL promoter.
When Wt and β POU1F1 expression vectors were co-
transfected no significant effect on PRL promoter activity was
shown relatively to Wt alone. A significant inhibition of
POU1F1-Wt induced trans-activation was observed when
POU1F1-γ or POU1F1-δ expression vectors were co-trans-
fected with POU1F1-Wt ( p<0.05). POU1F1-γ induced a 38%
reduction (from 36.4 to 22.4 fold) while POU1F1-δ induced a
60% reduction (from 36.4 to 14.6 fold) on the Wt transcriptional
activity. These results suggest that both variants (POU1F1-γ and
POU1F1-δ) act as dominant negative repressors of the POU1F1-
Wt transcription factor on the PRL promoter activation.SDS-PAGE and probed with antibody against POU1F1. Four different isoforms
ons for the assessment of the corresponding protein regions. Different domains of
D1 and TAD2 regions and includes aa from 1 to 80. The POU specific domain
HD) extends from aa 214 to 273 and includes three α helices. Isoform β should
d present only 216 aa (loss of aa from 72 to 146) and 141 aa (loss of aa from 72 to
17E. Bastos et al. / Gene 382 (2006) 12–19In order to confirm the negative repressor activity of these
splicing variants, increasing amounts of thePOU1F1-γ expression
vector were transfected (Fig. 3-A). Beginning with 0.15 μg of
PRL-Luc reporter vector and 0.3 μg of pRSV-Wt expression
vector, the result obtained was 23-fold activation. This value
decreased 26%, 39% and 65% when 0.3 μg, 0.6 μg and 1.2 μg of
pRSV-γ were added, respectively. The same type of experiment
was performed with POU1F1-δ, starting again with 0.15 μg of
PRL-Luc and 0.3 μg of pRSV-Wt. The resulting activation ofPRL
promoter suffered a decline of 24%, 44% and 69%, with addition
of 0.3μg, 0.6μg and 1.2μg ofPOU1F1-δ, respectively (Fig. 3-B).
3.3. Trans-activation of the growth hormone promoter
The transcriptional activity of all four POU1F1 splicing
variants on the GH promoter was also analysed by cell line
transfection assays, using RAT-6 fibroblast cell line, which
showed the lowest basal levels of GH promoter activity. Fig. 4
shows the result of the trans-activation of luciferase reporter
construct, under the GH promoter control, by the different
POU1F1 ORFs expression vectors.
POU1F1-Wt and POU1F1-β showed a strong (12 and 13
fold, respectively) trans-activation activity on the GH promoter.
POU1F1-γ and POU1F1-δ did not display transcriptional
activation of the GH promoter. When Wt and β POU1F1
expression vectors were added simultaneously, the GH promot-
er activity increased to 26 fold suggesting the existence of a
strong cooperation between both POU1F1 isoforms. In contrast,
POU1F1-γ and POU1F1-δ variants inhibited significantly
( p<0.001) the POU1F1-Wt transcriptional activation (52%
and 75%, respectively), acting as dominant negative repressors.
3.4. POU1F1 protein isoforms detected in the ovine pituitary
tissue
In order to detect the protein isoforms included in the ovine
pituitary, a Western blot assay was performed using an antibody
against POU1F1-Wt (Fig. 5-A). Four different protein bands
were detected with an apparent molecular weight of 36, 32, 17
and 14 kDa. A no-primary antibody control was tested, pre-
senting no detection signal (data not showed).
Fig. 5-B shows a schematic illustration of the four POU1F1
ORFs studied in the present work. The POU1F1-Wt protein
(291 aa) have the trans-activation domain (TAD) and POUS and
POUHD DNA-binding domains. The other three POU1F1
proteins are characterized in terms of the structural modifica-
tions relatively to POU1F1-Wt. The insertion of 26 aa into the
TAD results in POU1F1-β isoform that consequently present
317 aa. POU1F1-γ presents 216 aa as a consequence of the loss
of 75 aa from positions 72 to 146 of the Wt. The POU1F1-δ
isoform presents only 141 aa because 150 aa, between positions
72 and 221 of the POU1F1-Wt, are deleted (Fig. 5-B).
4. Discussion
Alternative pre-mRNA splicing is a very common process
that was initially considered an exception and nowadays is ratherthe rule. It is now accepted that more than 74% of the human
genes have splicing variants (Johnson et al., 2003; Kampa et al.,
2004). As with other transcription factor genes, differential
splicing of the POU1F1 gene gives rise to mRNAs and protein
variants with potential different biological activities.
In this paper we show: first, the existence of four splicing
mRNAs of POU1F1 gene in the pituitary of O. aries. The size
of the ORFs is 876 nt (Wt) and 954 nt (β) as a consequence of a
78 nt in-frame insertion. γ ORF has 651 nt as a consequence of
the loss of 225 nt from exon 3 and δ ORF has only 426 nt due to
the loss of 450 nt from exons 3, 4 and 5 simultaneously.
Second, the existence of four different protein in the ovine
pituitary corresponding, approximately to the expected MWs
for the four isoforms: Wt and β variants with 32 and 36 kDa,
and two smaller proteins γ and δ with 24 and 16 kDa. The two
last values are above the observed MWs in the Western blot
(17 kDa for the γ isoform and 14 kDa for the δ isoform). The
possible explanations for this observation are a disturbed mo-
bility of the lower bands in the SDS-PAGE and a post-trans-
lational modification of POU1F1 proteins.
Third, the protein level of the β isoform is eight times lower
than Wt in the ovine pituitary, confirming the results obtained in
rat pituitary tumour GH3 cells (Morris et al., 1992; Konzak and
Moore, 1992). Nevertheless, the amount of β protein is high for
a transcription factor, once POU1F1 total protein represents
approximately 0.5% of the total nuclear proteins of different
pituitary cell lines (Fox et al., 1990). The fact that the β POU1F1
variant has been found in different mammals with a high level
of conservation and that a very similar insertion of 28 aa is
constitutively present in the same position in the POU1F1 of
birds and fishes (Chiu et al., 2002), raises the possibility of an
important functional role of this variant. This hypothesis was
analysed in the present work regarding the PRL and GH pro-
moter transcriptional activation achieved by both Wt and β
variants.
Four, the ovine POU1F1-β isoform has a reduced capacity to
trans-activate the PRL promoter (12% of the Wt) but it shows a
strong trans-activation of the GH promoter, similar to Wt. In
addition, we observed that the β variant can cooperate strongly
(significance p<0.001) with POU1F1-Wt on the trans-
activation of GH promoter. β variant showed no significant
effect on the PRL promoter, comparing with Wt alone. The
function of POU1F1-β variant has been analysed by other
authors. Morris et al. (1992), Konzak and Moore (1992) and
Theill et al. (1992) agreed that, similarly to our results, the rat β
variant has only 5 to 10% of the Wt capacity to trans-activate
the PRL promoter. In agreement with our results, Haugen et al.
(1994) observed that, in HeLa cells, the β variant stimulated
GH promoter but had almost no effect on PRL promoter. When
both isoforms are co-expressed, contradictory results were
described: Theill et al. (1992) and Vila et al. (1993) observed a
dominant negative repressor effect of theβ variant, while Konzak
and Moore (1992) observed that Wt and β are not antagonists,
they can function together and interact in the activation of the rat
PRL promoter when co-expressed, in agreement with the results
of the present work. Diamond and Gutierrez-Hartmann (2000)
stated that, in pituitary cell lines, POU1F1-β represses PRL
18 E. Bastos et al. / Gene 382 (2006) 12–19promoter, but in non-pituitary cells, like HeLa cells, the rat β
variant presented a higher capacity to activate PRL promoter.
They performed an epitope-scanning and an alanine-scanning
mutagenesis of the β domain and showed that some aa residues
were essential for this behaviour. Three out of five aa residues
pointed out, by the authors, as the most important, are changed in
the O. aries β domain, presented in this work. These findings
confirm that the precise sequence of this domain is decisive for
the properties of repression or enhancement of the POU1F1
isoform.
Fifth, the two smaller variants of POU1F1 (γ and δ) are not
capable to trans-activate the PRL or GH promoters. Both pro-
teins are dominant negative repressors of POU1F1-Wt,
reducing significantly the trans-activation of both PRL and
GH promoters. A variant similar to γ was previously described
in pig pituitaries as δ3 (Yu et al., 2001). This variant did not
show DNA-binding activity on rat GH or PRL promoters and
did not interfere with Wt-POU1F1 function on a band shift in
vitro assay. Our results, obtained by using a transcriptional
functional assay, suggest a protein competition between Wt and
γ (or δ) POU1F1 and a mediator transcription factor or a nuclear
protein involved in a structural organization of the chromatin.
There are some examples of transcriptional activators and
repressors that are encoded by the same gene, namely, the I-
POU and its alternative splice form (twin of I-POU), in Dro-
sophila melanogaster, that act as inhibitor and activator of gene
transcription (Treacy et al., 1992). Regarding the POU1F1
gene, Voss et al. (1993) described an alternative spliced form
(Pit-1Δ4) in rat, lacking exon 4, and confirmed that it was not
competent in the activation of prolactin promotor. Day and Day
(1994) showed that this transcript was a potential mediator of
repression of prolactin gene expression in rat. In the present
work, the δ variant lacks equally exon 4, besides exons 5 and 6
and shows the same behaviour.
An important question still remain to be answered: why are
there so many alternative splicing forms of the POU1F1 gene?
The explanation should be connected to the many different
functions of POU1F1 gene in the pituitary tissue: 1) the fine-
regulation of GH and PRL promoters. Extracellular signals
(from the hypothalamus or the neurohypofisis) may regulate the
expression of specific POU1F1 isoforms, increasing or decreas-
ing the level of transcription of GH and PRL genes and
promoting changes on the level of GH and PRL hormones; 2) the
self-regulation of the POU1F1 gene expression during the
organogenesis of the pituitary in early development stages; 3)
the cell-type specific gene expression in thyrotrophs, somato-
trophs and lactotrophs cells of the adult pituitary; 4) regulation
on different physiological states of the animal. The age and sex
of animals may also have an impact on the pattern of the
POU1F1 gene-splicing variants; and 5) the POU1F1 isoforms
can also regulate, indirectly, the expression of many different
genes in the pituitary. Diamond and Gutierrez-Hartmann (2000)
showed that POU1F1-β altered the histone acetylation state of
the proximal prolactin promoter and Kievit and Maurer (2005)
believe that POU1F1 likely can modulate the chromatin
structure. It is reasonable to postulate that different splicing
forms of POU1F1 gene can specifically modulate the chromatinstructure, facilitating the recruitment and subsequent transcrip-
tional activation by other transcription factors in pituitary cells.
It is increasingly clear that the GH secretion of anterior pituitary
is under control of multiple hypothalamic releasing hormones,
paracrine factors and peripheral hormones/factors acting directly on
the somatotroph cells. It may be questioned whether different sub-
types of somatotrophs exist and are stimulated by different secreta-
gogues.Multiple hypothalamic peptides stimulate GH release from
the somatotroph acting via GH releasing hormone-receptors, GH
secretagogue (GHS) receptor and pituitary adenylate cyclase ac-
tivating peptide (PACAP) receptor. It is possible that different
isoforms of POU1F1 transcription factor will regulate the transcrip-
tional expression of specific secretagogues-receptor genes. In addi-
tion, this might support the existence of different sub-types of
somatotrophs responding to different hypothalamic secretagogues
with specific POU1F1 isoforms in the cells.
Further studies in ruminant and other animal models will
contribute to a better understanding of the molecular mechan-
isms controlling the hormonal secretion in the anterior pituitary.
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